Skip to main content
. 2022 Oct 26;29(2):401–409. doi: 10.1158/1078-0432.CCR-22-2509

Figure 2.

Figure 2. A, Kaplan–Meier curve for overall survival (OS) between common and ultrarare sarcomas. B and C, Kaplan–Meier curve for OS (B) and progression-free survival (C) for matched versus unmatched trials in URS.

A, Kaplan–Meier curve for overall survival (OS) between common and ultrarare sarcomas. B and C, Kaplan–Meier curve for OS (B) and progression-free survival (C) for matched versus unmatched trials in URS.